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BACKGROUND AND PURPOSE
Hypoxic conditions favour the reduction of nitrite to nitric oxide (NO) to elicit vasodilatation, but the mechanism(s)
responsible for bioconversion remains ill defined. In the present study, we assess the role of aldehyde dehydrogenase 2
(ALDH2) in nitrite bioactivation under normoxia and hypoxia in the rat and human vasculature.
EXPERIMENTAL APPROACH
The role of ALDH2 in vascular responses to nitrite was studied using rat thoracic aorta and gluteal subcutaneous fat resistance
vessels from patients with heart failure (HF; 16 patients) in vitro and by measurement of changes in forearm blood flow (FBF)
during intra-arterial nitrite infusion (21 patients) in vivo. Specifically, we investigated the effects of (i) ALDH2 inhibition by
cyanamide or propionaldehyde and the (ii) tolerance-independent inactivation of ALDH2 by glyceryl trinitrate (GTN) on the
vasodilator activity of nitrite. In each setting, nitrite effects were measured via evaluation of the concentration–response
relationship under normoxic and hypoxic conditions in the absence or presence of ALDH2 inhibitors.
KEY RESULTS
Both in rat aorta and human resistance vessels, dilatation to nitrite was diminished following ALDH2 inhibition, in particular
under hypoxia. In humans there was a non-significant trend towards attenuation of nitrite-mediated increases in FBF.
CONCLUSIONS AND IMPLICATIONS
In human and rat vascular tissue in vitro, hypoxic nitrite-mediated vasodilatation involves ALDH2. In patients with HF in vivo,
the role of this enzyme in nitrite bioactivation is at the most, modest, suggesting the involvement of other more important
mechanisms.
Abbreviations
ALDH, aldehyde dehydrogenase; eNOS, endothelial NOS; FBF, forearm blood flow; GTN, glyceryl trinitrate; HF, heart
failure; MABP, mean arterial BP; MetHb, methaemoglobin; NaNO2, sodium nitrite; NO2−, nitrite; Sper/NO,
Spermine-NONOate; XOR, xanthine oxidoreductase.
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Introduction
Nitrite can be chemically reduced in vivo to nitric oxide (NO)
to elicit vasodilatation (Lundberg et al., 2011; Totzeck et al.,
2012; Bailey et al., 2014). However, in vitro this conversion
process is relatively slow, perhaps explaining why relatively
high, supraphysiological nitrite concentrations are required
to relax pre-constricted isolated blood vessels (Furchgott and
Bhadrakom, 1953; Maher et al., 2008; Ormerod et al., 2011).
We and others have demonstrated that infused nitrite acts as
a vasodilator in healthy volunteers (Gladwin et al., 2000;
Cosby et al., 2003; Larsen et al., 2006; Dejam et al., 2007;
Maher et al., 2008), with greater potency as an arteriolar vaso-
dilator in forearm resistance vessels of patients with heart
failure (HF) compared with those of normal subjects (Maher
et al., 2013). Although several candidate mechanisms have
been postulated, the exact mechanism(s) responsible for bio-
activation of nitrite in man remains ill defined.
Under conditions of profound hypoxia and/or acidosis,
the conversion of nitrite to NO may occur via acid dispro-
portionation. Under less extreme conditions, various factors
have been reported to convert nitrite to NO. These include
xanthine oxidoreductase (XOR), aldehyde oxidase, endothe-
lial NOS (eNOS) and haem proteins (Doyle et al., 1981; Basu
et al., 2007; Li et al., 2008; Pinder et al., 2009; Lundberg et al.,
2011; Tiso et al., 2011; Totzeck et al., 2012). Previous studies
have demonstrated that mitochondrial aldehyde dehydroge-
nase 2 (ALDH2) may be an important additional source of
nitrite-derived NO in rat heart (Perlman et al., 2009) and the
vasculature (Golwala et al., 2009), but whether the oxidative
environment in the vasculature of HF patients may alter the
role for ALDH2 remains unknown. Interestingly, ALDH2 is
also known to act as a reductase of organic nitrates, such as
glyceryl trinitrate (GTN; Chen et al., 2002), and currently
GTN is used to treat HF patients. However, prolonged expo-
sure of the vasculature to GTN leads to inactivation of
ALDH2. Although it has been argued that ALDH2 inactiva-
tion is the principal mechanism for the development of
nitrate tolerance (Chen et al., 2002; DiFabio et al., 2003),
other investigators have demonstrated hysteresis between the
onset/offset of ALDH2 inactivation by GTN and the time
course of GTN tolerance (D’Souza et al., 2011), potentially
permitting the utilization of GTN pre-exposure as an ALDH2-
inactivating manoeuvre without induction of GTN tolerance.
Herein, we first explored the putative role of ALDH2 as a
contributor to nitrite bioactivation under normoxic and
hypoxic conditions, utilizing in vitro isolated rat vessels. To
translate our findings into the clinical setting, we explored
the role of ALDH2 in a proof-of-principle study in HF patients
in vitro (isolated vessel) and in vivo forearm blood flow (FBF;
measured by venous occlusion plethysmography). We chose
to evaluate HF patients, first because of the potential thera-
peutic relevance, and second because we have previously
shown that in vivo arteriolar responses to nitrite are increased
in patients with HF versus healthy controls (Maher et al.,
2013).
Methods
The animal studies were approved by the UK Home Office
and conducted according to the Animals (Scientific Proce-
dures) Act of 1986 and European Commission guidelines. A
total of 35 animals were used in the experiments described
here. The human investigations conformed to the Declara-
tion of Helsinki and were approved by the South Birmingham
Research Ethics Committee (10/H1207/50) and registered
with the UK Clinical Research Network (UK CRN 9587). All
patients gave written informed consent after satisfying the
inclusion and exclusion criteria as described below.
Tension myography
Male Sprague–Dawley rats (250–300 g) were killed by an over-
dose of anaesthetic by an i.p. injection of sodium pentobar-
bital (100 mg·kg−1). The thoracic aorta was carefully removed
and placed immediately in cold Krebs bicarbonate buffer (pH
7.4, 95% O2; 5% CO2) of the following composition
(mmol·L−1): NaCl (119), KCl (4.7), CaCl2 (2.5), KH2PO4 (1.18),
MgSO4 (1.19), NaHCO3 (25.1), glucose (11). Thoracic aortas
were cleaned from adhering connective tissue and cut into
three to four ring segments. Aortic rings were mounted in a
myograph (Multi-Myograph 610M, Danish Myotechnology,
Aarhus, Denmark) containing 5 mL Krebs bicarbonate buffer
(37°C, pH 7.4) and gassed with 95% O2/5% CO2. After an
equilibration period of 45 min, vessels were normalized as
previously described (Madhani et al., 2003). Following nor-
malization, each vessel was primed with KCl (4.8 mmol·L−1)
Tables of Links
TARGETS
GPCRsa Enzymesb
AT2 receptor Angiotensin converting enzyme 1 (ACE1)
Aldehyde dehydrogenase 2 (ALDH2)
Endothelial NOS (eNOS)
LIGANDS
ACh Nitric oxide (NO)
Aspirin PGF2α
Cyanamide Phenylephrine (PE)
Glyceryltrinitrate (GTN) Spironolactone
Lidocaine
These Tables list key protein targets and ligands in this article which are hyperlinked to corresponding entries in http://
www.guidetopharmacology.org, the common portal for data from the IUPHAR/BPS Guide to PHARMACOLOGY (Pawson et al., 2014) and are
permanently archived in the Concise Guide to PHARMACOLOGY 2013/14 (a,bAlexander et al., 2013a,b).
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before a supramaximal concentration of phenylephrine (PE;
10 μmol·L−1; Sigma Aldrich, Dorset, UK) was added. Once the
contractile tone had stabilized, ACh (1 μmol·L−1; Sigma
Aldrich) was added to the organ bath to assess the integrity
of the endothelium. If the constrictor responses to PE were
not maintained or ACh elicited relaxations <50% of the
PE-induced pre-contractile tone, the preparation was dis-
carded. Tissues were then washed for 30 min (by addition of
fresh Krebs bicarbonate buffer at 15 min intervals) after
which cumulative concentrations of PE (0.001–1 μmol·L−1)
were added to the myograph. These tissues were then washed
over 60 min to restore basal tone before being contracted
by PE, to approximately 80% of the maximum PE-induced
response. Once a stable response to PE was achieved, a
cumulative concentration–response curve to sodium
nitrite (NaNO2; Sigma Aldrich) was constructed (0.001–
100 μmol·L−1) under normoxic conditions (95% O2/5% CO2).
Under hypoxic conditions (95% N2/5% CO2; resulting in ≈1%
tissue bath O2; Maher et al., 2008), the vessels were incubated
for 30 min before exposure to the EC80 of PE (to achieve
similar tension observed at 95% O2) and the administration
of NaNO2.
To delineate the role of ALDH2 in nitrite-mediated vas-
orelaxation, concentration–response curves to NaNO2 were
constructed before and after 30 min of incubation with
cyanamide (1 mmol·L−1; ALDH2 inhibitor; DiFabio et al.,
2003; Sigma Aldrich) or propionaldehyde (1 mmol·L−1;
ALDH2 substrate that acts as a competitive inhibitor; DiFabio
et al., 2003; Sigma Aldrich) under normoxic and hypoxic
conditions.
To determine whether GTN pre-exposure of tissues leads
to an attenuation of the response to nitrite (via inactivation
of ALDH2), aortic rings were exposed to hypoxic conditions
as described earlier and then incubated in the presence or
absence of 30 or 100 μmol·L−1 of GTN for a period of 1 h
(Keith et al., 1982). Thereafter, blood vessels were washed
every 15 min for 1 h. After pre-contraction to the EC80 of
PE, a concentration–response curve to NaNO2 was
constructed.
In vitro and in vivo analysis in HF patients
The effect of ALDH2 inhibition on nitrite-mediated vasore-
laxation was investigated in HF patients: (i) in vitro in isolated
resistance vessels obtained from gluteal subcutaneous fat
tissue and (ii) in vivo by measuring changes in FBF during
intra-arterial infusion of sodium nitrite with and without
GTN pretreatment (to decrease ALDH2 activity).
Patient demographics
Patients were grouped as follows: (i) biopsy group (in vitro
myography; n = 16); (ii) plethysmography study: saline group
(n = 8) and GTN group (n = 13); Table 1). Inclusion criteria:
systolic HF [left ventricular ejection fraction (LVEF) <40], aged
between 40 and 80 years, and non-smoker. Exclusion criteria:
treatment with long-acting nitrates, past history of adverse
reactions to organic nitrates, hypotension (systolic BP
<110 mmHg), concomitant warfarin/clopidogrel therapy or
with bleeding diathesis, and obstructive sleep apnoea. All
subjects were asked to refrain from alcohol, and foods with a
high nitrate/nitrite content for 24 h, and caffeine for 12 h
before the study.
Effect of ALDH2 inhibition in isolated
resistance vessels
In a subgroup of nitrite/nitrate naïve HF patients (i.e. no
infusions or treatment of NaNO2 and/or GTN), subcutaneous
gluteal fat biopsies were obtained under local anaesthetic (2%
lidocaine) and placed in cold Krebs bicarbonate buffer as
previously described (Greenstein et al., 2009). Immediately
after harvesting the subcutaneous fat biopsies, small resist-
ance arteries (∼250 μm ID; 2 mm long) were isolated from the
fat, and mounted onto a myograph (Greenstein et al., 2009).
In most cases, two vessels from each biopsy were studied. The
myograph protocol for normalization, priming of vessels
with KCl, the assessment of supramaximal concentration of
PE and the endothelial integrity, was assessed as above.
Cumulative concentration–response curves to NaNO2 were
constructed (0.001–100 μmol·L−1) under normoxic and
hypoxic conditions as described earlier.
To investigate whether attenuation of nitrite efficacy
during hypoxia was caused by the effects of ALDH2 inhibition
on downstream signalling in the NO cascade, concentration–
response curves to the NO donor, spermine-NONOate
[N-(2-aminoethyl)-N-(2-hydroxy-2-nitrosohydrazino)-1,2-
ethylenediamine (Sper/NO); 0.001–1 μmol·L−1; Calbiochem
(EMD Millipore)], were constructed in the absence and pres-
ence of the ALDH2 inhibitor, cyanamide, under hypoxic
conditions.
The effect of ALDH2 inactivation by GTN
on FBF
To determine the effects of ALDH2 inactivation by GTN on
arteriolar responsiveness in patients from HF, forearm vascu-
lar responsiveness was assessed using the plethysmography.
The studies on HF patients were performed in a quiet
temperature-controlled (22–24°C) laboratory. All subjects
were placed in a semi-recumbent position enabling the
administration of hypoxia to participants. Changes in FBF
were determined in both arms by venous occlusion plethys-
mography (DE Hokanson, Bellevue, WA, USA) and BP, heart
rate (HR) and oxygen saturation were monitored as previ-
ously described (Maher et al., 2008). A 27 gauge arterial
needle (Coopers Engineering, Birmingham, UK) mounted
onto a 16 gauge epidural catheter and sealed with dental wax
was then inserted aseptically into the brachial artery of the
non-dominant arm and was kept patent by the continuous
infusion of normal saline (Baxter Healthcare, Deerfield, IL,
USA; 0.9%). An i.v. cannula (20 gauge) was inserted in the
contralateral arm for venous blood sampling. Saline was
infused via the intra-arterial line at 1 mL·min-1 for 10 min for
baseline measurements before infusion of NaNO2. Data were
acquired from both arms, and any changes observed were
corrected for those occurring in the contralateral control arm
and presented as a ratio of FBF (FBF-R) during infusion com-
pared with baseline (Maher et al., 2008).
As depicted in Figure 1, following 10 min of rest, two
doses of NaNO2 (Martindale Pharmaceuticals, Buckingham,
UK) were infused into the brachial artery of the non-
dominant arm (784 nmol·min−1 then 7.84 μmol·min−1 for
20 min each; the infusion rate was 1 mL·min−1 as described
previously; Maher et al., 2008). FBF was measured in both
arms. Following the second dose of NaNO2 (7.84 μmol·min−1),
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the patients switched from breathing room air to inspiring
12% oxygen via a facemask connected to a two-way valve.
Upon achieving target oxygen saturation of 83–88%, the
study proceeded with the 7.84 μmol·min−1 infusion of nitrite
for a further 10 min. Thereafter, patients were randomized to
receive either an i.v. infusion of 10 μg·min GTN (to decrease
ALDH2 activity; Merck-Lipha Pharmaceuticals Ltd, Mid-
dlesex, UK) as described previously (Philpott et al., 2007) or
Table 1
Patient demographics
In vitro analysis In vivo analysis
Biopsy-only group (n = 16) Saline group (n = 8) GTN group (n = 13)
Age (years) 64.5 ± 3.8 62 ± 4.0 66 ± 3.3
Male gender, n (%) 13 (81) 7 (88) 12 (92)
Mean weight (kg) 78.3 ± 3.8 74.6 ± 2.5 82.3 ± 3.3
Body mass index (kg·m–2) 27.8 ± 1.5 25.4 ± 0.5 27.1 ± 0.9
Ejection fraction (%) 26.4 ± 2.3 25.1 ± 2.5 27 ± 2.1
NYHA class
I 2 1 1
II 6 4 10
III 8 3 2
Heart rate (beats·min-1) 72 ± 2.8 62 ± 4.4 62 ± 2.0
MABP (mmHg) 95 ± 4.1 89 ± 2.9 88 ± 2.2
Aetiology, n (%)
Dilated cardiomyopathy 8 (50) 5 (62) 6 (46)
Ischaemic cardiomyopathy 6 (38) 3 (38) 6 (46)
Other 2 (13) 0 1 (8)
Medication, n (%)
ACEI/AT2 receptor antagonists 15 (94) 8 (1 00) 12 (92)
β-Blockers 10 (63) 5 (62) 10 (77)
Spironolactone/eplerenone 10 (63) 3 (38) 3 (23)
Loop diuretic 12 (75) 4 (50) 8 (62)
Aspirin 12 (75) 4 (50) 10 (77)
Data expressed as mean ± SEM.
ACEI, ACE inhibitors; MABP, mean arterial BP; NYHA, New York Heart Association classification.
Figure 1
Schematic protocol of the plethysmography study.
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saline (the placebo group; active ALDH2) for 4 h (15 mL·h−1).
Following a 30 min washout period (saline at 1 mL·min−1),
repeat infusions of NaNO2 were administered during nor-
moxia and hypoxia as described earlier.
Upon completion of the plethysmography protocol, the
intra-arterial needle was removed. Participants were allowed
to rest for 10 min following which a subcutaneous fat biopsy
was obtained (Figure 1) as described earlier. Philpott et al.
(2007) have previously reported that low-dose GTN infusion
rapidly inactivates ALDH2 and that this inactivation occurs
before the development of significant nitrate tolerance.
Therefore, to determine whether the infusion of GTN had
induced significant nitrate tolerance, GTN vasodilator
concentration–response curves were compared in resistance
vessels taken via gluteal biopsy in patients from the saline
(placebo group; active ALDH2) and GTN (inactive ALDH2)
infusion group. Briefly, the isolated tissue resistance vessels
were mounted in a myograph, the vascular rings were
assessed for endothelial integrity and then contracted sub-
maximally with PE and cumulative concentration–response
curves were constructed for GTN (0.001–1 μmol·L−1) from the
saline and GTN infusion HF patient group respectively.
Blood samples
Venous blood samples were taken at eight time points during
the plethysmography study (Figure 4) for determination of
venous methaemoglobin (MetHb) and pH (blood gas analyser
Bayer Rapidlab 865, Siemens, NY, USA), and determination of
total plasma 8-iso prostaglandin F2α (8-isoprostane EIA assay
kit protocol, Cayman Chemical, Ann Arbor, MI, USA).
Isolation of mitochondrial fraction
Rat aortic vessels that were treated as described earlier in the
tension myography studies were immediately snap frozen at
the end of the protocol for isolation of the mitochondrial
fraction. Frozen thoracic aorta was suspended in the mito-
chondrial buffer containing 10 mmol·L−1 MOPS (pH 7.2),
10 mmol·L−1 KCl, 1.5 mM MgCl2, 1 mmol·L−1 EDTA,
10 μg·mL−1 leupeptin, 10 μg·mL−1 aprotinin and 0.25 mol·L−1
sucrose, and gently homogenized with a Dounce homog-
enizer (30 strokes) as previously described (Paneni et al.,
2013). The homogenate was centrifuged at 750× g for 10 min
at 4°C to remove nuclei and unbroken cells, and the super-
natant was subsequently centrifuged at 10 000× g for 15 min.
The resultant mitochondrial pellet was used for the ALDH2
assay kit (see ALDH2 activity assay for details).
Mitochondrial ALDH2 activity assay
ALDH2 activity was determined in mitochondria isolated
from rat thoracic aorta following solubilization and extrac-
tion as specified in the manufacturer’s recommendations
(mitochondrial ALDH2 activity assay kit; Abcam, Cambridge,
UK). The homogenate was then incubated on ice for 20 min
and centrifuged at 16 000× g for 20 min at 4°C. Protein con-
centration of the supernatant was determined and 20 μg of
protein was used to detect ALDH2 activity. In this assay, the
generation of NADH is coupled to the 1:1 reduction of a
reporter dye to yield reaction product concentration, which
was monitored by measuring the absorbance increase at
450 nm.
Statistical analysis
All data are expressed as mean ± SEM, and significance was
accepted with P < 0.05. For the myography analysis,
concentration–response curves were analysed using two-way
ANOVA. For the in vivo FBF analysis, one-way ANOVA repeated
measures coupled with a Bonferroni post hoc test was used to
compare the effects of pre-saline/GTN or post-saline/GTN
infusion treatment. A paired non-parametric test (Wilcoxon
signed-rank test) was used to compare FBF following hypoxia
between pre-GTN infusion and post-GTN infusion. Statistical
analysis was undertaken using Prism software (version 4.0,
GraphPad Software, La Jolla, CA, USA).
Results
Evaluation of the role of ALDH2 in
nitrite-mediated bioactivation in rat aorta
As depicted in Figure 2, the vasorelaxant response to NaNO2
displays a biphasic concentration–response relationship. As
shown in Figure 2A, following incubation of vessels with the
ALDH2 inhibitor cyanamide during normoxic conditions,
vasorelaxation by NaNO2 was paradoxically enhanced at
nanomolar concentrations and significantly inhibited at
higher NaNO2 concentrations (10 and 30 μM) when com-
pared with controls (P < 0.05; by two-way ANOVA). Hypoxia
enhanced nitrite-induced relaxation but pretreatment with
cyanamide during hypoxia caused a significant attenuation
of nitrite’s efficiency to relax blood vessels at all concentra-
tions tested when compared with the control (P < 0.05; by
two-way ANOVA; Figure 2B). Similar results were obtained
using the ALDH2 substrate, propionaldehyde. Incubation of
vessels with propionaldehyde under normoxic conditions
blunted the vasorelaxant effect of low concentrations of
nitrite without affecting its efficacy at higher concentrations,
but these differences did not reach statistical significance (P >
0.05; by two-way ANOVA; Figure 2C). However, under hypoxic
conditions, propionaldehyde significantly attenuated the
response to nitrite in the nano- to micromolar concentrations
range when compared with control (P < 0.05; by two-way
ANOVA; Figure 2D) without affecting maximal relaxation
induced by the highest concentration of nitrite.
Effect of ALDH2 inhibition on
nitrite-mediated vasorelaxation in resistance
vessels from HF patients
Under both normoxic and hypoxic conditions, NaNO2
caused concentration-dependent relaxation of resistance
vessels from HF patients (Figures 3A and B). During normoxic
conditions, pretreatment with cyanamide tended to shift the
NaNO2 concentration–response curve to the right but this
was not statistically significant (Figure 3A). Under hypoxic
conditions, pretreatment with cyanamide caused a marked
and concentration-dependent attenuation of the relaxation
responses to NaNO2 when compared with control (P < 0.05;
by two-way ANOVA; Figure 3B). To assess whether this effect
was nitrite specific, concentration–response curves to the NO
donor Sper/NO were constructed in the presence or absence
of cyanamide. Cyanamide had no inhibitory activity on the
vasorelaxant responses to Sper/NO under hypoxic conditions
(Figure 3C).
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Effect of GTN pretreatment on
nitrite-mediated vasorelaxation in rat aorta
In addition to the aforementioned inhibitor/substrate experi-
ments, we also assessed the effects of GTN (used as a tool to
decrease ALDH2 activity) on nitrite-mediated vasorelaxation.
Using a well-established in vitro model of nitrate tolerance in
rat isolated aorta (Keith et al., 1982; Irvine et al., 2007), blood
vessels were pretreated with GTN (30 or 100 μmol·L−1) for 1 h
followed by construction of a concentration–response curve
to NaNO2 under hypoxic conditions. Pretreatment with GTN
(30 and 100 μmol·L−1) significantly attenuated the response
to NaNO2 compared with controls (P < 0.05; by two-way
ANOVA; Figure 4A), particularly at higher concentrations. As
shown in Figure 4B, mitochondrial ALDH2 activity was sig-
nificantly decreased following pretreatment with GTN (30
and 100 μmol·L−1) when compared with control (NaNO2; P <
0.05; by one-way ANOVA).
Effects of GTN-induced ALDH2 inactivation
on nitrite-mediated vasodilatation in the
human forearm
FBF corrected for changes in the non-infused arm (FBF ratio)
increased dose-dependently with NaNO2 in the saline
(placebo) and GTN groups respectively (Figure 5A and B). As
depicted in Figure 5A, one-way ANOVA repeated measures
showed that 7.84 μmol·min−1 nitrite significantly increased
FBF in the pre-saline infusion group from 0.94 ± 0.09 at
baseline to 1.69 ± 0.21 during normoxic (P < 0.05 compared
with baseline) and 1.76 ± 0.22 during hypoxic conditions (P
< 0.05 compared with baseline; Figure 5A). Following 4 h i.v.
saline infusion (placebo group; active ALDH2), a similar
profile in FBF-R response to NaNO2 was observed when com-
pared with pre-saline infusion. Nitrite 7.84 μmol·min−1 sig-
nificantly increased FBF in the post-saline infusion group
from 1.02 ± 0.04 at baseline to 1.93 ± 0.14 during normoxic
(P < 0.001 compared with baseline) and 2.05 ± 0.18 during
hypoxic conditions (P < 0.001 compared with baseline).
In the GTN group (Figure 5B), prior to administration of
i.v. GTN, one-way ANOVA repeated measures showed that
7.84 μmol·min−1 nitrite infusion significantly increased FBF
from 1.24 ± 0.08 at baseline to 2.34 ± 0.29 during normoxic (P
< 0.05 compared with baseline) and 2.48 ± 0.36 (P < 0.01
compared with baseline) during hypoxic conditions. Follow-
ing 4 h infusion of GTN to inactivate ALDH2, although
7.84 μmol·min−1 nitrite infusion significantly increased FBF
from 1.20 ± 0.11 (baseline) to 1.95 ± 0.15 during normoxic
conditions (P < 0.001 when compared with baseline) and 1.72
± 0.15 during hypoxia (P < 0.05 when compared with base-
line). However, GTN treatment tended to attenuate the
increase in FBF following nitrite infusion (7.84 μmol·min–1)
when compared with the pre-GTN infusion. Using a paired
non-parametric test (Wilcoxon signed-rank test), we com-
pared pre- and post-GTN infusion for each of baseline and
Figure 2
ALDH2 inhibition attenuates nitrite-induced vasorelaxation in rat aortae. Concentration–response curves to sodium nitrite in the presence or
absence of ALDH2 inhibitor, cyanamide, during (A) normoxia (n ≥ 5), (B) hypoxia (n ≥ 5), and ALDH2 substrate, propionaldehyde, during (C)
normoxia (n ≥ 5) and (D) hypoxia (n ≥ 5). Relaxation is expressed as mean ± SEM percentage reversal of PE-induced tone. *P < 0.05, **P < 0.01
and ***P < 0.001 control versus cyanamide or propionaldehyde by two-way ANOVA.
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784 nmol and 7.84 μmol at normoxic conditions and at
hypoxic conditions respectively. There was no significant dif-
ference between pre-GTN versus post-GTN infusion at baseline
(1.24 ± 0.09 and 1.20 ± 0.11, respectively; P = 0.79), pre-GTN
versus post-GTN infusion with 784 nmol·min−1 (2.16 ± 0.72
and 1.35 ± 0.10, respectively; P = 0.34), or at pre-GTN versus
post-GTN infusion with 7.84 μmol·min−1 (2.34 ± 0.29 and 1.95
± 0.15, respectively; P = 0.28). During hypoxic conditions,
GTN treatment attenuated the increase in FBF following nitrite
infusion (7.84 μmol·min−1) but this effect did not reach statis-
tical significance (2.48 ± 0.36 and 1.72 ± 0.15, pre- and post-
GTN infusion, respectively; P = 0.08; Figure 5C).
GTN infusion does not induce tolerance in
resistance vessels
To confirm that our low-dose GTN infusion protocol did not
induce systemic nitrate tolerance, a gluteal biopsy was
obtained at the end of the plethysmography protocol and
isolated resistance vessels were used for myography experi-
ments. There was no attenuation of the vasodilator response
to GTN compared with that in the control vessels isolated
from the saline infusion group (P = 0.87; Figure 5D).
Assessment of haemodynamics, venous pH,
8-isoprostanes and methaemoglobin
formation during nitrite infusion in
HF patients
HR and mean arterial BP (MABP) did not alter significantly
from baseline following administration of NaNO2 in the
saline and GTN groups (Table 2). Arterial oxygen saturations
remained stable throughout the normoxia period in the
saline group, but fell significantly following administration of
12% oxygen in both the saline and GTN groups (from 97 ±
0.5% to 87 ± 1.1%, P < 0.001 and from 97 ± 0.3 to 87 ± 0.6,
P < 0.001 respectively). There was no significant change in
either venous pH (saline group n = 5–7; GTN group n = 9–11;
P > 0.05) or 8-isoprostane levels (saline group n = 4–6; GTN
group n = 7–9; P > 0.05) in both the saline and GTN groups.
Following 4 h saline infusion, venous MetHb levels
increased during escalating NaNO2 dose infusions from
0.31 ± 0.04% to 1.39 ± 0.21% (baseline and 7.84 μmol·min−1
nitrite, normoxia) of total Hb. Highest levels were reached
following 7.84 μmol·min−1 nitrite infusion during hypoxic
conditions (1.63 ± 0.17%; P < 0.001; n = 5–7). In the GTN
group, a similar trend was observed, MetHb levels increased
Figure 3
ALDH2 inhibition decreases nitrite-induced vasorelaxation in resistance vessels from HF patients. Concentration–response curve to sodium nitrite
in the presence or absence of cyanamide during (A) normoxia (n = 7) and (B) hypoxia (n = 9). (C) Concentration–response curve to Sper/NO in
the presence or absence of cyanamide during hypoxic conditions (n ≥ 6). Relaxation is expressed as mean ± SEM percentage reversal of PE-induced
tone. *P < 0.05 and **P < 0.01 control versus cyanamide by two-way ANOVA.
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from 0.37 ± 0.06% to 1.51 ± 0.18% (baseline and
7.84 μmol·min−1 nitrite, respectively, normoxia) with the
highest levels of MetHb (1.57 ± 0.15%; P < 0.001; n = 9–11)
reached following 7.84 μmol·min−1 nitrite infusion during
hypoxic conditions. There was no significant difference
between the two groups. Pre-infusion data were also similar
for the haemodynamics and MetHb pre-saline/GTN (data not
shown).
Discussion
We previously demonstrated that intra-brachial artery infu-
sion of nitrite causes forearm vasodilatation in both healthy
subjects and in HF patients, with greater potency in the latter
(Maher et al., 2013), but the mechanism(s) underlying these
effects remains incompletely understood. Based on these
observations, we here explored the role of ALDH2 in nitrite
bioactivation under normoxia and hypoxia in both rats and
human vasculature. Our findings suggest that ALDH2 plays
a major role in nitrite-mediated vasorelaxation in vitro.
However, this effect was clearly less marked in vivo, and we
postulate that this could be due to the presence of multiple in
vivo mechanisms.
Several nitrite reductases have been identified, including
eNOS, XOR, aldehyde oxidase and haem proteins such as
deoxyhaemoglobin and myoglobin, to bioactivate nitrite
under hypoxia (Doyle et al., 1981; Basu et al., 2007; Pinder
et al., 2009; Lundberg et al., 2011; Tiso et al., 2011; Baliga
et al., 2012; Ghosh et al., 2013). All of these agents alone
and/or in combination are capable of bioconverting nitrite to
NO in vitro, but their physiological role remains incompletely
understood. Previous studies have reported that ALDH2 may
be an important source of nitrite-derived NO in the heart
(Perlman et al., 2009) and vasculature (Badejo et al., 2010),
but whether the oxidative environment in the vasculature
alters the effects of ALDH2 on nitrite-mediated vasorelaxa-
tion remains unclear. Therefore, in the present study we first
explored the role of ALDH2 in nitrite-mediated vasorelaxa-
tion in vitro in rat isolated conduit vessels (aorta) during
normoxic and hypoxic conditions. Our in vitro data showed
that the ALDH2 inhibitor, cyanamide and the ALDH2 sub-
strate, propionaldehyde significantly reduced the potency of
nitrite under hypoxic conditions. These data indicate the
potential for ALDH2 to be involved in hypoxic nitrite vaso-
dilator responses.
Much of our current understanding about nitrite’s mode
of action as a vasodilator is based on animal experimental
work and considerably less information is available on the
mechanism of vasodilatation by nitrite in human tissue. Nev-
ertheless, studies in healthy human subjects have shown that
nitrite causes marked venodilatation and moderate dose-
dependent arteriolar dilatation, and these effects are aug-
mented by hypoxia or exercise in healthy subjects (Cosby
et al., 2003; Maher et al., 2008). We have previously shown
that in vivo arteriolar responses to nitrite are increased in
patients with HF versus healthy controls (Maher et al., 2013).
Because of the potential therapeutic relevance of these find-
ings, we now chose to translate these observations to the
clinical setting by evaluating the role of ALDH2 in HF
patients in vitro and in vivo. Because the vascular responses to
intra-arterial nitrite are most accurately assessed by measur-
ing changes in FBF (i.e. resistance vessel effects), we first
investigated whether the effects of ALDH2 inhibition on
nitrite-mediated vasorelaxation observed in the rat isolated
conduit vessels were replicated in vitro in resistance vessels
from patients with HF. We confirmed that the inhibition of
ALDH2 significantly attenuates nitrite-mediated vasorelaxa-
tion during hypoxic conditions. Importantly, cyanamide did
not alter the potency of the NO donor Sper/NO, ruling out
non-specific effects of this inhibitor on NO bioactivity. These
observations concur with functional data obtained by
Huellner et al. (2008), where pharmacological inhibition of
ALDH2 did not alter the potency to the NO donor DEA/NO in
isolated human veins. To our knowledge, this is the first study
in man to assess the effects of NaNO2 in isolated resistance
vessels from HF patients. Interestingly, the magnitude differ-
ence in vasorelaxation response to NaNO2 observed in the
normoxic versus hypoxic group of blood vessels from HF
patients was similar. Moreover, the response to NaNO2 when
comparing rat thoracic aorta versus HF patient resistance
vessels was also different. This might be related to different
vascular beds, species differences or the heterogeneity in vas-
cular response between healthy and pathophysiology tissues.
Regarding the latter, based on our previous findings (Maher
Figure 4
Tolerance-independent inactivation of ALDH2 attenuates vasorelaxa-
tion in rat aortae. (A) Concentration–response curve to NaNO2 in the
presence or absence of GTN during hypoxic conditions. Relaxation is
expressed as mean ± SEM percentage reversal of PE-induced tone (n
= 10); *P < 0.05, ***P < 0.001 versus control, two-way ANOVA. (B) The
effect of sodium nitrite (control), in the presence or absence of GTN
during hypoxic conditions, on mitochondrial ALDH2 activity (mean ±
SEM from n = 4–6 animals; *P < 0.05 vs. control by one-way ANOVA).
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et al., 2013), we believe that the reason why the magnitude
difference in nitrite-induced relaxation is not that different
between normoxia versus hypoxia in isolated resistance
vessels from HF patients when compared with conduit vessels
(thoracic aorta) from healthy rats is because, first, the vaso-
motor response to nitrite is altered and enhanced and there-
fore the magnitude is not that different when compared with
hypoxia as suggested from our previous in vivo studies (Maher
et al., 2013).
Previous studies have reported that prior GTN exposure
induces nitrate tolerance in association with attenuated
ALDH2 activity in the vasculature (DiFabio et al., 2003;
Huellner et al., 2008; D’Souza et al., 2011). Therefore, using a
well-established in vitro model of nitrate tolerance in rat iso-
lated aorta (Keith et al., 1982; Irvine et al., 2007), we demon-
strated attenuation of nitrite-mediated vasorelaxation
following pretreatment with GTN during hypoxic conditions.
To substantiate the role of ALDH2 as a key effector in nitrite-
mediated vasorelaxation, we here show that this attenuation
in vascular response is associated with reduced mitochondrial
ALDH2 activity.
It is important to recognize that there are 19 known
human ALDH isoenzymes, of which only a few, such as
ALDH2 (Koppaka et al., 2012), have been thoroughly charac-
terized biochemically and by susceptibility to pharmacologi-
cal inhibition. To date, no antagonists have been developed
to specifically inhibit each ALDH isoenzyme without affect-
ing others. Moreover, clear sensitivity differences to different
ALDH2 inhibitors have been reported, for example, GTN
bioactivation in rat liver was sensitive to chloral hydrate but
not to daidzin (Kollau et al., 2005). In the current study,
we chose to use cyanamide (an irreversible inhibitor) and
propionaldehyde (a reversible competitive inhibitor) as both
are capable of inhibiting ALDH and have been used to
examine the role of ALDH2 in organic nitrate-induced vas-
orelaxation in rat aorta (Chen et al., 2002; DiFabio et al.,
Figure 5
GTN infusion attenuates nitrite-induced vasorelaxation in the resistance vasculature of HF patients. Forearm vasodilator measurements following
nitrite infusion in HF patients subjected to 4 h infusion of (A) saline (n = 8 patients) or (B) GTN (n = 11 patients) treatment. *P < 0.05, **P < 0.01,
***P < 0.001 compared with baseline. (C) Comparison of pre- and post-GTN infusion following 7.84 μmol·min−1 sodium nitrite during hypoxic
conditions (n = 8 and n = 11 patients, respectively; P = 0.08). (D) Concentration–response curve to GTN in isolated resistance vessels from HF
patients (saline n = 7; GTN n = 11 patients).
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2003). Notwithstanding possible species differences in sensi-
tivity to both inhibitors and vasodilators (including further
differences in bioactivation mechanisms), we further comple-
mented these results by a mechanism-based ALDH2 inhibi-
tion approach employing an in vitro tolerance model and
have reached the same conclusion, that is, that ALDH2 inhi-
bition exerts inhibitory actions of NaNO2-mediated vasore-
laxation in vitro.
Assessing the involvement of specific enzymes in mediat-
ing the vasodilator effects of nitrite in man in vivo remains a
challenge. The ALDH2 inhibitor disulfiram is commonly used
in clinical studies without ill effect (Johansson, 1992;
Mackenzie et al., 2005), but its use in HF patients is contra-
indicated (Huffman and Stern, 2003). Therefore, in the
present study we elected to use a low-dose GTN infusion as it
has been previously reported to rapidly inactivate vascular
ALDH2, and that this inactivation occurs prior to the devel-
opment of significant nitrate tolerance and prior to detect-
able impairment of GTN bioconversion (Philpott et al., 2007).
We measured the vasodilator activity of nitrite in HF patients
and tested whether pre-infusion of GTN (in order to decrease
ALDH2 activity) attenuates forearm vasodilator responses to
nitrite during normoxic and hypoxic conditions. Despite the
well-recognized presence of both endothelial dysfunction
and NO resistance in HF patients (Marti et al., 2012),
adequate vascular activity in response to nitrite was observed
in our study. During normoxic conditions, we found an
approximate twofold increase in forearm vasodilator
responses following 7.84 μmol·min−1 of NaNO2 in both the
saline and GTN group compared with their baseline
responses. These results are similar to our previous findings in
healthy volunteers (Maher et al., 2008). Under hypoxic con-
ditions, inhibition of ALDH2 with GTN (post-GTN infusion
group) tended to reduce the forearm vasodilator response but
was not significant when compared with the pre-GTN infu-
sion group. Our observation in gluteal resistance vessels taken
at the end of the in vivo study confirmed that the low-dose
GTN regime had not induced systemic tolerance, which is
consistent with a previous study demonstrating that the same
regime inhibited ALDH2 without inducing GTN tolerance
(Philpott et al., 2007).
Study limitations
Despite strict inclusion/exclusion criteria to standardize
experimental procedures, a degree of heterogeneity will exist
in the population studied in terms of cause and severity of HF.
Furthermore, we did not measure plasma levels of nitrite/
nitrate as the results are likely to have been affected by the
local and systemic metabolism of GTN to nitrite and nitrate,
masking any changes to circulating endogenous nitrite/
nitrate levels that may have occurred as a result of ALDH2
inhibition. Finally, we were unable to confirm in our in vivo
studies whether ALDH2 activity was actually attenuated by
GTN.
Conclusions
Our in vitro data confirm a role for ALDH2 in nitrite-mediated
vasorelaxation during hypoxic conditions in both rat aortaTa
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and human resistance vessels. Because nitrite is under con-
sideration as a therapeutic agent, the role for ALDH2 in the
bioactivation of nitrite during hypoxic vasodilatation is of
importance. Our in vitro experiments demonstrate that nitrite
could directly affect vasorelaxation without necessitating
interaction with blood constituents. However, we cannot dis-
count other non-enzymatic and/or nitrite reductase species
(e.g. haem proteins, eNOS, XOR and aldehyde oxidase),
which may contribute to the reduction in nitrite during
hypoxic conditions in vitro (Li et al., 2008; Pinder et al., 2009;
Baliga et al., 2012; Totzeck et al., 2012; Ghosh et al., 2013).
Furthermore, although our in vivo results demonstrate a (non-
significant) trend towards attenuation of the forearm vasodi-
lator response to nitrite following GTN treatment, we suggest
that this is probably due to a decrease in ALDH2 activity.
However, no firm conclusion can be drawn about the mecha-
nism sub-serving this effect in vivo. The fact that this effect
was non-significant (P = 0.08) may reflect the presence of
multiple in vivo mechanisms. In particular, we cannot exclude
the role for deoxyhemoglobin in vivo as blood-borne NO
species derived from nitrite may contribute to its vasodilator
effects (Angelo et al., 2006). In addition, previous work by
Gladwin’s group has demonstrated that the inhibition of
eNOS or XOR does not attenuate nitrite-induced vasodilata-
tion in healthy volunteers (Cosby et al., 2003; Dejam et al.,
2007). However, although it seems that XOR may not con-
tribute to nitrite reduction in health, a recent work by Ghosh
et al. (2013) reported that XOR does mediate nitrite reduction
during pathological conditions (hypertensive animals and
patients). Thus, their relative contribution to the hypoxic
vasodilator effect of nitrite in man in vivo, in particular in
patients with HF, remains unresolved and is yet to be fully
explored.
Moreover, the observations of the current study suggest
that pre-exposure to GTN (even without inducing tolerance)
might attenuate nitrite vasodilator effects. This finding may
be of clinical importance when considering nitrite as a thera-
peutic intervention in patients who may have received recent
therapy with organic nitrates. Further studies are required to
elucidate the extent to which ALDH2 is involved in nitrite
reduction to NO in vivo in man.
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